| Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution C Abbosh, NJ Birkbak, GA Wilson, M Jamal-Hanjani, T Constantin, ... Nature 545 (7655), 446-451, 2017 | 1671 | 2017 |
| Allele-specific HLA loss and immune escape in lung cancer evolution N McGranahan, R Rosenthal, CT Hiley, AJ Rowan, TBK Watkins, ... Cell 171 (6), 1259-1271. e11, 2017 | 1145 | 2017 |
| The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours SJ Thomas, JA Snowden, MP Zeidler, SJ Danson British journal of cancer 113 (3), 365-371, 2015 | 618 | 2015 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 536 | 2018 |
| Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer S Danson, D Ferry, V Alakhov, J Margison, D Kerr, D Jowle, M Brampton, ... British journal of cancer 90 (11), 2085-2091, 2004 | 481 | 2004 |
| Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer AJ Clayton, S Danson, S Jolly, WDJ Ryder, PA Burt, AL Stewart, ... British journal of cancer 91 (4), 639-643, 2004 | 475 | 2004 |
| Perivascular M2 macrophages stimulate tumor relapse after chemotherapy R Hughes, BZ Qian, C Rowan, M Muthana, I Keklikoglou, OC Olson, ... Cancer research 75 (17), 3479-3491, 2015 | 462 | 2015 |
| Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors FA Vargas, AJS Furness, I Solomon, K Joshi, L Mekkaoui, MH Lesko, ... Immunity 46 (4), 577-586, 2017 | 410 | 2017 |
| Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes T Le Chevalier, G Scagliotti, R Natale, S Danson, R Rosell, R Stahel, ... Lung cancer 47 (1), 69-80, 2005 | 407 | 2005 |
| Tamoxifen (‘Nolvadex’): a review: Antitumour treatment M Clemons, S Danson, A Howell Cancer treatment reviews 28 (4), 165-180, 2002 | 315 | 2002 |
| DT-diaphorase: a target for new anticancer drugs S Danson, TH Ward, J Butler, M Ranson Cancer treatment reviews 30 (5), 437-449, 2004 | 217 | 2004 |
| Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial DA Fennell, S Ewings, C Ottensmeier, R Califano, GG Hanna, K Hill, ... The Lancet Oncology 22 (11), 1530-1540, 2021 | 197* | 2021 |
| Methotrexate is a JAK/STAT pathway inhibitor S Thomas, KH Fisher, JA Snowden, SJ Danson, S Brown, MP Zeidler PloS one 10 (7), e0130078, 2015 | 176 | 2015 |
| Senescence and cancer: a review of clinical implications of senescence and senotherapies L Wyld, I Bellantuono, T Tchkonia, J Morgan, O Turner, F Foss, J George, ... Cancers 12 (8), 2134, 2020 | 171 | 2020 |
| Locoregionally recurrent breast cancer: incidence, risk factors and survival M Clemons, S Danson, T Hamilton, P Goss Cancer treatment reviews 27 (2), 67-82, 2001 | 168 | 2001 |
| Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma S Danson, P Lorigan, A Arance, A Clamp, M Ranson, J Hodgetts, ... Journal of clinical oncology 21 (13), 2551-2557, 2003 | 132 | 2003 |
| Outcome and biomarker analysis from a multicenter phase 2 study of ipilimumab in combination with carboplatin and etoposide as first-line therapy for extensive-stage SCLC E Arriola, M Wheater, I Galea, N Cross, T Maishman, D Hamid, L Stanton, ... Journal of Thoracic Oncology 11 (9), 1511-1521, 2016 | 120 | 2016 |
| Temozolomide: a novel oral alkylating agent SJ Danson, MR Middleton Expert review of anticancer therapy 1 (1), 13-19, 2001 | 119 | 2001 |
| Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study PG Corrie, A Marshall, JA Dunn, MR Middleton, PD Nathan, M Gore, ... The Lancet Oncology 15 (6), 620-630, 2014 | 117 | 2014 |
| Assessment of therapeutic response in patients with metastatic bone disease A Clamp, S Danson, H Nguyen, D Cole, M Clemons The lancet oncology 5 (10), 607-616, 2004 | 115 | 2004 |
